

# Monica Hellesøy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9593624/publications.pdf>

Version: 2024-02-01

16  
papers

271  
citations

1307594

7  
h-index

1058476

14  
g-index

17  
all docs

17  
docs citations

17  
times ranked

474  
citing authors

#	ARTICLE	IF	CITATIONS
1	Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2022, 12, 388-401.	9.4	73
2	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. <i>Journal of Thoracic Oncology</i> , 2020, 15, 973-999.	1.1	66
3	Efficient in vivo vascularization of tissue-engineering scaffolds. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2011, 5, e52-e62.	2.7	49
4	Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. <i>Haematologica</i> , 2020, 105, 1527-1538.	3.5	19
5	Titration of Complex Mass Cytometry Panels. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 792-796.	1.5	16
6	Cellular context-mediated Akt dynamics regulates MAP kinase signaling thresholds during angiogenesis. <i>Molecular Biology of the Cell</i> , 2015, 26, 2698-2711.	2.1	12
7	Sex disparity in acute myeloid leukaemia with <i>FLT3</i> internal tandem duplication mutations: implications for prognosis. <i>Molecular Oncology</i> , 2021, 15, 2285-2299.	4.6	11
8	Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1729-1749.	2.5	8
9	<i>FLT3</i> ITD mutations in acute myeloid leukaemia molecular characteristics, distribution and numerical variation. <i>Molecular Oncology</i> , 2021, 15, 2300-2317.	4.6	5
10	Akt1 Activity Regulates Vessel Maturation in a Tissue Engineering Model of Angiogenesis. <i>Tissue Engineering - Part A</i> , 2014, 20, 2590-2603.	3.1	3
11	Early response evaluation in AML using mass cytometry. <i>HemaSphere</i> , 2019, 3, 3-5.	2.7	3
12	Single Cell Detection of the p53 Protein by Mass Cytometry. <i>Cancers</i> , 2020, 12, 3699.	3.7	3
13	Single Cell Signaling Pharmacodynamics in a Phase 1b Trial of the Axl Inhibitor BGB324 in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 3995-3995.	1.4	1
14	A 36-Dimensional Cytometry by Time of Flight (CyTOF) Analysis of De Novo Acute Myeloid Leukemia (AML) Patients Eligible for Intensive Chemotherapy. <i>Blood</i> , 2018, 132, 1502-1502.	1.4	1
15	Preclinical characterisation and development of a novel myelodysplastic syndrome-derived cell line. <i>British Journal of Haematology</i> , 2021, 193, 415-419.	2.5	0
16	Single Cell-Level Signaling Profiling of Acute Myeloid Leukemia Following Treatment with Axl Kinase Inhibitor BGB324. <i>Blood</i> , 2015, 126, 4931-4931.	1.4	0